5-Fluoro-ibogamine






Names

    • 5-Fluoro-ibogamine

Attributes

  • Canonical SMILES

    CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(CCC4=C3NC5=CC=C(F)C=C45)C2

  • InChI

    InChI=1S/C19H23FN2/c1-2-12-7-11-8-16-18-14(5-6-22(10-11)19(12)16)15-9-13(20)3-4-17(15)21-18/h3-4,9,11-12,16,19,21H,2,5-8,10H2,1H3/t11-,12+,16+,19+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 19.03
  • #RotBonds: 1
  • MW: 298.40500000000003
  • HBD: 1
  • HBA: 1
  • logP: 4.0671000000000035
  • Chemical Formula: C19H23FN2


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. catharinensis Brazil 403124 UEC117862

External Databases


References

  • Precursor-directed Biosynthesis in Tabernaemontana catharinensis as a New Avenue for Alzheimer's Disease-modifying Agents. Planta Med, 2021 (PMID 33321518).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.69
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.89
    Human Oral Bioavailability 50% Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -1.86
    Distribution Blood-Brain Barrier (Central Nervous System) -2.9
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.56
    Plasma Protein Binding 73.15
    Steady State Volume of Distribution 3.28
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Substrate
    CYP 2C9 Inhibitor Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 8.88
    Organic Cation Transporter 2 Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 1.11
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.14
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 6.64
    Micronucleos Toxic
    NR-AhR Toxic
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -1.14
    Rat (Acute) 3.47
    Rat (Chronic Oral) 1.59
    Fathead Minnow 4.06
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 390.36
    Hydration Free Energy -5.21
    Log(D) at pH=7.4 3.42
    Log(P) 3.61
    Log S -3.53
    Log(Vapor Pressure) -7.69
    Melting Point 217.48
    pKa Acid 11.04
    pKa Basic 8.04